Skip to main content

Closed

ALGS: Aligos Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth-44.6% / yr

Operating margin-2033.4%

ROIC-212.9%

Financially safe

Stretched

Debt / equity0.14×

Interest coverage0.0×

Current ratio2.56×

Aligos Therapeutics, Inc.

ALGSNASDAQ Global Select·USD·Closed

Aligos Therapeutics, Inc.

ALGSNASDAQ·USD·Closed

$4.23

−2.08%

$4.23

−$0.09 (2.08%)

52W Range

3thpctl

Volume

0.28×avg

Mkt Cap

26.18MUSD

P/E

-0.5TTM

Div Yield

–ann

52W Range

3thpctl

Volume

0.28×avg

Market Cap

26.18MUSD

P/E Ratio

-0.5TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings